BusinessNon-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, OtherBy Nasdaq OMXSep 11, 2017, 11:57 AM UTC
BusinessNew Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer PatientsBy Nasdaq OMXApr 3, 2017, 5:08 PM UTC
BusinessPeregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:05 PM UTC
BusinessVaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung CancerBy Nasdaq OMXOct 6, 2016, 1:45 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of BavituximabBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
